Leerink Partners Keeps Their Buy Rating on Evolus (EOLS)

Leerink Partners analyst Marc Goodman maintained a Buy rating on Evolus on October 7. The company’s shares closed yesterday at $6.23.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Goodman is a 5-star analyst with an average return of 13.7% and a 54.36% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Alkermes, ACADIA Pharmaceuticals, and Biogen.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evolus with a $16.90 average price target.

Based on Evolus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $69.39 million and a GAAP net loss of $17.14 million. In comparison, last year the company earned a revenue of $66.91 million and had a GAAP net loss of $11.35 million

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EOLS in relation to earlier this year. Most recently, in August 2025, Brady Stewart, a Director at EOLS bought 30,000.00 shares for a total of $204,300.00.